This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
ICAD, Inc. Showcases New Profound Cloud, Enhanced Profound Detection Workstation Features at SBI Annual Symposium CI
ICAD, Inc. and Densitas, Inc. Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation CI
ICAD, Inc. Announces Commercial Availability of ProFound Cloud CI
Transcript : ICAD, Inc., Q4 2023 Earnings Call, Mar 12, 2024
Earnings Flash (ICAD) ICAD Posts Q4 Revenue $4.7M, vs. Street Est of $4.3M MT
ICAD, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
ICad to Present Three Mammography Studies at Radiology Conference; Shares Rise MT
ICAD, Inc. Appoints Hedvig Hricak to the Board of Directors CI
ICAD, Inc. Appoints Michael John Doyle to its Board of Directors CI
Icade Appoints New CFO MT
ICAD, Inc. Expands Executive Sales Leadership Team as Business Grows CI
ICAD, Inc. AI-Powered Solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare CI
ICAD, Inc. to Present New Studies Valuating its Artificial Intelligence Powered ProFound Breast Health Suite CI
Icade Closes Divestment of Grand Central Building in France MT
ICAD Partners With CancerIQ to Expand Breast Healthcare Service MT
RTX's Collin Aerospace Unit Wins Services Contract for Saudi Arabia's NEOM Bay Airport MT
Transcript : ICAD, Inc., Q3 2023 Earnings Call, Nov 13, 2023
Earnings Flash (ICAD) ICAD Posts Q3 Revenue $4.1M, vs. Street Est of $5.91M MT
ICAD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
ICAD, Inc. Announces Resignation of Michael Klein as Member of the Board CI
Elekta Enters $5.5 Million Deal to Acquire iCAD's Xoft Business MT
Elekta AB (OM:EKTA B) acquired Xoft, Inc. from iCAD, Inc. for $5.8 million. CI
ICAD, Inc.(NasdaqCM:ICAD) dropped from S&P Global BMI Index CI
Health Canada Grants Device License for iCAD's Profound Risk 2.0, Revolutionizing Breast Cancer Risk Via A 1-2 Year Assessment CI
Transcript : ICAD, Inc., Q2 2023 Earnings Call, Aug 14, 2023
Chart iCAD, Inc.
More charts
iCAD, Inc. is a global medical technology company, which provides cancer detection and therapy solutions. The Company is focused on providing breast cancer detection solutions built on artificial intelligence (AI) that empowers radiologists to find cancers. Its solutions include advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, and a range of high-performance, AI and computer-aided detection (CAD) systems and workflow solutions for 2D and 3D mammography, magnetic resonance imaging and computed tomography (CT). The Company’s Breast AI Suite offers a triple threat of clinically proven cancer detection, density assessment, and risk evaluation solutions, designed to accelerate discovery and improve outcomes. It also offers ProFound AI, a digital breast tomosynthesis (DBT) cancer detection and workflow solution.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.54 USD
Average target price
4.833 USD
Spread / Average Target
+213.85%
Consensus
  1. Stock Market
  2. Equities
  3. ICAD Stock
  4. News iCAD, Inc.
  5. ICAD Names Stephen Sarno Interim CFO